Shanghai BiOligo Biotech Co., Ltd. (referred to as "BiOligo"), a leading supplier of in vitro diagnostics and nucleic acid drug raw materials, recently closed a RMB 300 million Series A financing. The funding was led by The Carlyle Group, a global leading investment institution, with participation from CICC Capital and BioVenture.

CEC Capital served as the exclusive financial advisor in this transaction for BiOligo.

Founded in 2011, BiOligo's founding team has extensive technical expertise, and multinational pharmaceutical commercial experience, having held senior positions at GE, TMO, and other Fortune 500 medical enterprises. BiOligo focuses on the in vitro diagnostics industry, particularly in precision medicine, specializing in providing essential materials and professional technical services to downstream customers in the gene/molecular diagnostics industry chain.